- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugEli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.STAT · 1mo ago↗ source
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potentialDetailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.STAT · 1mo ago↗ source
- Opinion: How the Amish think about vaccines, health care costs, and much moreThere may be nearly 2 million Amish Americans by 2075. That has large public health implications.STAT · 1mo ago↗ source